Uncategorized Archives - Page 37 of 146

ThursdayApr 20, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate, and built, owns, and operates its GMP biologics manufacturing facility BiondVax has an exclusive collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), to develop a pipeline of innovative nanosized antibody therapies BiondVax’s experience, assets, and pipeline represent a rare opportunity for a company of its size BiondVax Pharmaceuticals (NASDAQ: BVXV), a…

TuesdayApr 18, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars - the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of…

FridayApr 14, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans The in vivo results have shown that the company’s inhaled COVID-19 therapy, formulated using alpaca-derived nanosized antibodies (“NanoAbs”), resulted in milder and shorter illness, virtually eliminated the virus from the lungs, and prophylactically protected against illness Since he was appointed CEO in early 2021, Reichman…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

TuesdayApr 11, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023 So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S. As an aside, the…

FridayMar 31, 2023 9:00 am

Progressive Care Inc. (RXMD) Recent News Indicates Something Big Is Brewing

Restructuring whiz takes helm at RXMD New CEO takes no salary or other forms of compensation Company sees infusion of $6 million cash from key investors A synergistic tech-healthcare collaboration grows as financials show upward trend Looks like something big is brewing at Florida-based Progressive Care (OTCQB: RXMD). Focused on health services, the company offers healthcare services and technology that supports the managed healthcare industry to reduce costs and improve quality of care. The company has been steadily building both its pharmacy and data-management divisions as revenues continue to improve. However, a couple of extremely revealing events recently transpired that…

TuesdayMar 28, 2023 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SP-26 as an alternative treatment for fibromyalgia The study, which is being carried out in conjunction with Experimur, has looked into the feasibility of using a time-released, dosage-controlled formulation of ketamine as a suitable treatment for the chronic medical condition Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced…

FridayMar 24, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking…

TuesdayMar 21, 2023 9:00 am

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. 31,…

MondayMar 20, 2023 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults (https://ibn.fm/jvjFN). Studies like this that provide critical information regarding CV disease highlight the ongoing urgency of HeartBeam’s efforts. HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

Progressive Care Inc. (RXMD) Recent News Indicates Something Big Is Brewing

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search